Angiotensin-converting enzyme inhibitors for ovarian cancer? — a new adjuvant option or a silent trap

BACKGROUND: Ovarian cancer is a huge therapeutic and financial problem for which approved treatments have already achieved their limit of efficiency. A cost-effective strategy to extend therapeutic options in this malignancy is drug repurposing aimed at overcoming chemoresistance. Here, angiotensin-...

Descripción completa

Detalles Bibliográficos
Autores principales: Regulska, Katarzyna, Michalak, Marcin, Kolenda, Tomasz, Kozłowska-Masłoń, Joanna, Guglas, Kacper, Stanisz, Beata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Via Medica 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10547424/
https://www.ncbi.nlm.nih.gov/pubmed/37795232
http://dx.doi.org/10.5603/RPOR.a2023.0059

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10547424/
https://www.ncbi.nlm.nih.gov/pubmed/37795232
http://dx.doi.org/10.5603/RPOR.a2023.0059

Ejemplares similares